In vivo perturbation of rat hepatocyte canalicular membrane function by diclofenac.
Clinical use of diclofenac is associated with a small but significant incidence of hepatotoxicity. It has been reported that in vivo diclofenac treatment results in decreased activity of the extracellular canalicular membrane protein dipeptidylpeptidase IV in rats as a consequence of protein adduct formation by its electrophilic metabolite diclofenac acyl glucuronide. The present study has investigated the effects of in vivo diclofenac treatment (15 mg/kg/day for 7 days) on the activity of an another four rat extracellular canalicular membrane proteins. Animals administered diclofenac (n = 6) had 47.9, 60.4, and 51.6% lower (p < 0.05) canalicular activities of gamma-glutamyltransferase, Mg(2+)-ATPase, and leucine aminopeptidase, respectively, compared with controls (n = 6), but there was no difference in alkaline phosphatase activity. In general, protein adduct formation by acyl glucuronides has been associated with decreased protein function, and the lower canalicular enzyme activities in diclofenac-treated rats may suggest that gamma-glutamyltransferase, Mg(2+)-ATPase, and leucine aminopeptidase are also targets of adduct formation by acyl glucuronide metabolites of diclofenac. However, intracellular redistribution and/or decreased synthesis of these enzymes would also be consistent with our results. The ability of diclofenac acyl glucuronide (200 microg/ml) to form covalently bound adducts with gamma-glutamyltransferase (10 mg/ml) was demonstrated following in vitro incubations (16 h, pH 7.4, and 37 degrees C) in which 20.7 +/- 2.1 ng of diclofenac were covalently bound per milligram of protein. In these in vitro studies, the low concentration of protein adducts formed was not associated with any significant change in gamma-glutamyltransferase activity.
Sallustio
B C
BC
Department of Clinical Pharmacology, The Queen Elizabeth Hospital, Woodville, South Australia. benedetta.sallustio@nwahs.sa.gov.au
Holbrook
F L
FL
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001648:Bile Canaliculi / Q000187:drug effects* / Q000201:enzymology; D004008:Diclofenac / Q000494:pharmacology*; D020719:Glucuronides / Q000378:metabolism; D022781:Hepatocytes / Q000187:drug effects* / Q000201:enzymology; D066298:In Vitro Techniques; D008111:Liver Function Tests; D008297:Male; D008566:Membranes / Q000187:drug effects / Q000201:enzymology; D008862:Microsomes, Liver / Q000187:drug effects / Q000378:metabolism; D008930:Mitochondria, Liver / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D015430:Weight Gain / Q000187:drug effects; D005723:gamma-Glutamyltransferase / Q000378:metabolism
D000894:Anti-Inflammatory Agents, Non-Steroidal; D020719:Glucuronides; D004008:Diclofenac; D005723:gamma-Glutamyltransferase